home All News open_in_new Full Article

Ipsen delivers strong sales in the first quarter 2025 and confirms its full

Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma. Confirmation of full-year 2025 financial guidance. PARIS, FRANCE, 16 April 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care […]


today 3 w. ago attach_file Economics

attach_file Culture
attach_file Economics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Culture
attach_file Economics


ID: 2577734803
Add Watch Country

arrow_drop_down